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esponsibility of InstAbstract Unlike human immunodeﬁciency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus
(HCV) infection is a curable disease. Current direct antiviral agent (DAA) targets are focused on HCV
NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The ﬁrst generation of DAAs
includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in
2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was
added to standard PEG-IFN/ribavirin. More effective and less toxic second generation DAAs supplanted
these drugs by 2013. The second generation of DAAs includes sofosbuvir (Sovaldi), simeprevir (Olysio),
and ﬁxed combination medicines Harvoni and Viekira Pak. These drugs increase cure rates to over 90%
without the need for interferon and effectively treat all HCV genotypes. With these drugs the “cure HCV”
goal has become a reality. Concerns remain about drug resistance mutations and the high cost of these
drugs. The investigation of new HCV drugs is progressing rapidly; ﬁxed dose combination medicines in
phase III clinical trials include Viekirax, asunaprevirþdaclatasvirþbeclabuvir, grazoprevirþelbasvir and
others.
& 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical
Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).8
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Anti-HCV agents 271. Introduction
Hepatitis C is a liver disease caused by the hepatitis C virus
(HCV). HCV is a positive-strand RNA virus encoding a poly-
protein that undergoes proteolytic cleavage to 10 polypeptides,
each with a distinct function. The structural proteins consist of two
envelope glycoproteins, both of which are targets of the host
antibody response, and the core protein, which interacts with
progeny viral genomes for assembly of the virus. The nonstruc-
tural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B form a
complex with viral RNA to initiate viral replication in a
cytoplasmic membranous structure1.
HCV causes both acute and chronic infections. Acute infection
is a non-life threatening disease and ranges from being asympto-
matic to causing a self-limited hepatitis. About 15%–45% of
acute infected patients spontaneously clear HCV within several
months after infection. The remaining 55%–85% of patients
develop chronic infection. Currently, almost 140 million people
in the world have chronic HCV infection, including 4 million
Americans and over 10 million Chinese. Of those with chronic
infection, 15%–30% develop cirrhosis and the risk of hepatocel-
lular carcinoma increases more than 20 fold within 20 years of
infection. Unlike hepatitis A and B, a vaccine for HCV is not
available. The therapy for HCV infection relies only on antiviral
drugs. Before 2011, the standard regimen of anti-HCV therapy
was pegylated interferon alpha (PEG-IFNα) plus ribavirin (RBV)
for a period of 24–48 weeks. This dual therapy (DT) produced
cure rates of between 70%–80% for HCV genotypes 2 and 3, and
45%–60% for genotypes 1 and 4. Although some patients could
be cured of their infection, this DT regimen was associated with
substantial toxicity and many patients were not candidates for
therapy because of contraindications to interferon including pre-Table 1 DAAs in clinical use and in phase III trials.
Generic name Brand name Mechanism
Boceprevir Victrelis NS3/4A protease
Telaprevir Incivek NS3/4A protease
Simeprevir Olysio NS34A protease
Sofobuvir Sovaldi NS5B polymerase
Sofobuvir (GS-7977) Harvoni NS5B polymerase
þLedipasvir (GS-5855) þNS5A proteain
Ombitasvir (ABT-267) Viekira Pak NS5A protein
þParitaprevir (ABT-450) þNS3/4A protease
þRitonavir þa cytochrome P450 3A4
inhibitor
þDasabuvir (BT-333)) þNS5B polymerase







Grazoprevir (MK-5172) n/a NS3/4A protease
þElbasvir (MK-8742) þNS5A protein
Ombitasvir (ABT-267) Viekirax NS5A protein
þParitaprevir (ABT-450) þNS3/4A protease
þRitonavir þa cytochrome P450 3A4
inhibitor
n/a, not available.existing depression and certain auto-immune diseases. These
toxicities and contraindications combined with low response
rates (especially in genotype 1 and 4 infection) drove a search for
more effective and less toxic agents. Over the last several years,
basic HCV research has led to the discovery and clinical
development of a large number of new anti-HCV drugs, includ-
ing several direct-acting antivirals that are targeted against
several molecular targets. These include NS3/4A protease
inhibitors (PIs), NS5B polymerase inhibitors and NS5A
inhibitors.
The ﬁrst generation of NS3/4A PIs (boceprevir and telaprevir)
was approved for clinical use in 2011. In the middle of 2011,
PEG-IFN/RBV therapy for HCV genotype 1 infection was
supplanted by PEG-IFN–based triple therapies with the addition
of ﬁrst generation PIs—boceprevir (BOC) or telaprevir (TVR).
With the addition of boceprevir or telaprevir to PEG-IFN/RBV,
cure rates for HCV genotype 1 increased to 65%–75%. By 2013,
the second generation of DAA drugs including sofosbuvir
increased sustained virologic response (SVR) rates to 90%–
100%. A “second generation” PI, simprevir, resulted in similar
SVR rates when added to PEG-IFN/RBV. By 2014, IFN-free
regimens had essentially replaced interferon-based therapy. Sofos-
buvir/ledipasvir and sofosbuvir/simeprevir/RBV resulted in geno-
type1 SVR rates of 92%–100%. Combinations of ombitasvir,
paritaprevir/ritonavir/dasabuvir with/without RBV achieved SVR
rates as high as 100%. The next steps in the clinical development
of anti-HCV therapy are expected by late 2015–early 2016 with
the availability of pangenotypic ultra-rapid (4–8 weeks) single pill
regimens such as grazoprevir/MK8742, Sofosbuvir/GS5816 and
BMS791325/DAC/Asunaprevir. This review is focused on the
development of the above-mentioned DAA drugs (Table 1) in the
treatment of HCV infections in next several years.Status Pharmaceutical company
Approved in 5/2011, to be
discontinued in 12/2015
Merck
Approved in 5/2011, discontinued
in 10/2014
Vertex
Approved in 10/2013 Janssen and
MEDIVIR ab
Approved in 12/2013 Gilead Science
Approved in 10/2014 Gilead Sciences
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Figure 1 Structures of (A) boceprevir and (B) telaprevir.
Xingquan Zhang*282. First generation DAAs: boceprevir and telaprevir
Boceprevir (SCH 503034, Fig. 1A)2,3 and telaprevir (VX-950,
Fig. 1B)4,5 are HCV NS3/4A PIs. Both of these drugs show potent
inhibition of the HCV NS3/4A protease with Ki values of 14 and
7 nmol/L, respectively. They also exhibit ant-HCV activity in cell
culture with IC50 values of 200–280 nmol/L. In phase I clinical
trials, treatment with either boceprevir or telaprevir resulted in 1.5–
4.4 log10 IU/mL drops in plasma HCV RNA levels. Combining
boceprevir or telaprevir with PEG-IFNα with or without RBV
increased anti-HCV effects and decreased the emergence of resis-
tance. The results of phase III trials demonstrated that triple therapy
with either boceprevir or telaprevir and PEG-IFNα and RBV
increased SVR rates from 30%–40% with PEG-IFNα and RBV
alone to 65%–76%. Although the two drugs were reasonably well
tolerated the continued presence of PEG-IFNα and RBV in the
combination regimen severely limited their clinical utility. When
clinical studies of the two drugs were completed, the US Food and
Drug Administration (FDA) approved boceprevir (trade name:
Victrelis) and telaprevir (trade name: Incivek, Incivo) for use in
combination with PEG-IFNα and RBV for adult patients chronically
infected with HCV genotype 1 in May of 2011. Since 2011, more
than 100,000 people globally have taken the two drugs. Vertex
Pharmaceuticals decided to stop selling Incivek on October 16,
2014. Merck plans to discontinue selling boceprevir for HCV
infection by December 2015. These decisions were based on the
appearance of the new and better next generation DAAs that will be
described in more detail below. These new drugs can be used in well
tolerated all oral, interferon-free regimens, such as sofosbuvir/
ledipasvir (Harvoni, Gilead) and Viekira Pak (AbbVie). These
regimens produce cure rates in the 90%–100% range when taken
for 8–24 weeks.3. Second generation DAAs
3.1. Sofosbuvir
Sofosbuvir (GS-7977, Fig. 2A)6,7 is a nucleotide analog that
inhibits HCV NS5B polymerase. After ingestion, it is rapidly
converted to GS-331007. GS-331007 is efﬁciently taken up by
hepatocytes and become GS-461203, the pharmacologically active
uridine analog 5'-triphosphate form after conversion by cellular
kinases. This triphosphate compound mimics the natural cellular
uridine nucleotide and is incorporated by the HCV RNA poly-
merase into the elongating RNA primer strand, resulting in chain
termination. Sofosbuvir displays potent inhibitory activity against
HCV RNA replication with an EC50 of 0.92 nmol/L and EC90 of
0.29 mmol/L. When assessed in an 8-day cytotoxicity assay, it
shows no cytotoxicity against Huh7, HepG2 and CEM cells even
at concentrations up to 100 mmol/L. In clinical trials of sofosbuvir/
PEG-IFN/RBV, patients with genotype 1 or 4 infection achievedSVR rates of 92%. The combination of sofosbuvir and RBV
achieved SVR rates of 100% for genotype 2 infection and 91% for
genotype 3 infection. Because GS-461203 does not inhibit host
DNA polymerases, RNA polymerases or mitochondrial RNA
polymerases, sofosbuvir is extremely well tolerated by patients.
On December 6, 2013, FDA approved sofosbuvir (brand name:
Sovaldi) for use in the treatment of chronic hepatitis C, genotypes
1, 2, 3 and 4, in combination with PEG-IFN and RBV, or with
RBV alone (depending on the genotype). Subsequently it has been
approved for use in combination with the viral NS5A inhibitor
ledipasavir in an interferon-free regimen for the treatment of
genotype 1 patients. Sofosbuvir is also highly effective in HCV
patients who are co-infected with HIV.3.2. Simeprevir
Simeprevir (TMC435, Fig. 2B)8,9 is a highly speciﬁc and potent
inhibitor of HCV NS3/4A protease. Ki values of 0.5 and 0.4 nmol/L
against the protease enzyme were determined in biochemical assays.
The EC50 of simeprevir for inhibiting HCV genotypes 1b and 1a in
cell culture models of HCV infection is 8 nmol/L. The selectivity
index is over 5000. Simeprevir is extensively distributed to the liver
and intestinal tract with a biovailability of 44% after a single oral
administration. Clinical results demonstrate that simeprevir is safe
and well tolerated, and achieved SVR rate (viral cure) of 79%–81%
in three pivotal phase III combination trials in hepatitis C-infected
patients. Semeprevir was also studied in interferon-free trials with
and without ribaviran. An SVR rate of 92% was achieved when it
was used in combination with sofosbuvir in genotype 1 patients. On
October 24, 2013, FDA approved simeprevir (trade name: Olysio,
Sovriad) for clinical use, and it is indicated for treating chronic HCV
infection as a part of a triple antiviral treatment regimen consisting
of two other drugs: PEG-IFN and RBV. It is primary efﬁcacious in
treating HCV genotype 1 infected subjects with compensated liver
disease, including cirrhosis. Simeprevir has been tested in inter-
feron-free regimens with other direct-acting antiviral agents includ-
ing daclatastir and sofosbuvir. A recent study has shown the
effectiveness of simeprevir therapy with PEG-IFN and RBV in
post-liver transplant patients with recurrent HCV.3.3. Harvoni
Harvoni (sofosbuvirþledipasvir; GS7977þGS-5855) is a ﬁxed-
dose combination tablet containing ledipasvir (90 mg) and sofos-
busvir (400 mg) for oral administration. As mentioned above,
sofosbuvir is a nucleotide analog inhibitor of HCV NS5B
polymerase. Ledipasvir (Fig. 2C)10 is an HCV NS5A inhibitor.
In HCV replicon assays, the EC50 values against genotypes 1a and
1b are 0.031 and 0.004 nmol/L, respectively. The median EC50
values against chimeric replicons are 0.018 and 0.006 nmol/L for
genotypes 1a and 1b. Ledipasvir has lower antiviral activity
Figure 3 Structures of (A) ombitasvir, (B) paritaprevir, (C) dasabuvir and (D) ritonavir.
Figure 2 Structures of (A) sofosbuvir (GS-7977), (B) simeprevir (TMC435) and (C) ledipasvir.
Anti-HCV agents 29compared to genotype 1 against genotypes 4a, 5a and 6a with
EC50 values of 0.39, 0.15 and 1.1 nmol/L, respectively. Ledipasvir
also exhibits substantially lower activity against genotypes 2a, 2b,
3a, and 6e with EC50 values of 21–249, 16–530, 168, and
264 nmol/L, respectively. The efﬁcacy of Harvoni against HCV
genotype 1 was demonstrated in three phase III trials in which
SVR rates of 93%–99% were achieved after 12 weeks of therapy.
Relapse rates of 0–2% were observed depending on baseline HCV
RNA levels, with or without liver cirrhosis and other factors11. The
US FDA approved Harvoni to treat chronic HCV genotype
1 infection on October 10, 2014.
3.4. Viekira Pak
Viekira Pak contains three new drugs—ombitasvir (Fig. 3A),
paritaprevir, (Fig. 3B), dasabuvir (Fig. 3C) and ritonavir (Fig. 3D),
a previously approved drug which is used to increase blood levels
of paritaprevir. Viekira Pak can be used with or without RBV, but
it is not recommended for patients with poor liver function
(decompensated cirrhosis).
Ombitasvir (Fig. 3A)12 is an HCV NS5A inhibitor with
picomolar potency, pan-genotypic activity, and EC50 values of
0.82–19.3 pmol/L against HCV genotypes 1 through 5 and
366 pmol/L against genotype 6a. Ombitasvir's in vivo activity
was demonstrated in an a 3-day monotherapy study at 5, 25, 50
and 200 mg dosed once daily in which decreases in HCV RNA ofup to 3.1 log10 IU/mL were observed. Paritaprevir (Fig. 3B)
13 is an
efﬁcacious inhibitor of HCV NS3/4A protease, with EC50 values
of 1.0, 0.21, 5.3, 19, 0.09 and 0.69 nmol/L against stable HCV
replicons with NS3 protease from genotypes 1a, 1b, 2a, 3a, 4a, and
6a, respectively. In a 3-day monotherapy study with HCV
genotype 1-infected patients, paritaprevir was co-administered
with ritonavir (Fig. 3D14, a cytochrome P450 3A4 inhibitor that
is required as a pharmacologic enhancer for pariteprevir). In this
study a mean maximum plasma HCV RNA decline of 4.02 log10
IU/mL was observed. Dasabuvir (Fig. 3C)15 is a nonnucleoside
HCV polymerase inhibitor with EC50 values of 2.2 and 7.7 nmol/L
against HCV genotypes Type 1a and 1b, respectively. In combina-
tion studies with other Abbvie DAA drugs comprising Viekera
Pak, 91%–100% of patients were cured including those considered
difﬁcult to treat. The recommended dosing for Viekira Pak is two
ombitasvir, paritaprevir, ritonavir 12.5 mg/75 mg/50 mg tablets
once daily and one dasabuvir 250 mg tablet twice daily16. The
FDA approved Viekira Pak to treat patients with HCV genotype
1 infection, including those with a type of advanced liver disease
called cirrhosis on December 19, 2014.4. Investigational new drugs in phase III trials
Currently, several new drugs have entered into phase III clinical
trials, but have not been approved by FDA to use in clinical.
Xingquan Zhang*304.1. Asunaprevirþdaclatasvirþbeclabuvir
Asunaprevir (BMS-650032, Fig. 4A)17 is a HCV NS3 protease
inhibitor, and it has Ki values of 0.4 and 0.24 nmol/L against HCV
genotypes 1a and 1b protease and IC50 values of 0.7, 0.3, 15, 78,
320, 1.6, 1.7 and 0.9 nmol/L for genotypes 1a, 1b, 2a, 2b, 3a, 4a,
5a and 6a. Daclatasvir (BMS-790052, Fig. 4B)18 inhibits the HCV
nonstructural protein NS5A. Recent research suggests that it
targets two steps of the viral replication process, enabling rapid
decline of HCV RNA. Daclatasvir inhibited the JFH-HCV 3a
hybrid replicons with EC50 ranging from 120 to 870 pmol/L, and
similar daclatasvir potencies were also observed with replicon cell
lines (EC50¼0.14–1.25 nmol/L). Beclabuvir (BMS-791325,
Fig. 4C)19 is a non-nucleoside inhibitor of HCV NS5B polymer-
ase. It inhibits genotype 1 HCV NS5B polymerase with nanomolar
potency, but shows no activity against the closely related RNA-
dependent RNA polymerase from the pestivirus, bovine viral
diarrhea virus, or human DNA polymerase. The clinical study that
evaluated cirrhotic patients in a 12-week regimen of this three drug
ﬁxed combination regimen showed SVR 12 rates of 98% of in
treatment-naïve and 93% in treatment-experienced cirrhotic
patients with RBV and 93% of treatment-naïve and 87% of
treatment-experienced cirrhotic patients without RBV20.4.2. Grazoprevirþelbasvir
Grazoprevir (MK-5172, Fig. 5A)21,22 is selective inhibitor of HCV
NS3/4A protease with broad activity across genotypes and resistant
variants. In the replicon assay, it demonstrated sub-nanomolar to
low-nanomolar EC50 values against genotypes 1a, 1b and 2a, and no
evidence for cellular cytotoxicity. Grazoprevir was administered
orally (1 mg/kg twice daily for 7 days) to three chimpanzeesFigure 4 Structures of (A) asunaprevir
Figure 5 Structures of (A) grinfected by wild-type genotype 1a or 1b HCV with viral titers
104–106 IU/mL, and all animals experienced an immediate, pro-
found reduction in plasma HCV RNA levels (4–5 log10 IU/mL).
Elbasvir (MK-8742, Fig. 5B)23,24 interferes with the HCV protein
NS5A. In laboratory experiments with cells and HCV, it is active
against most strains of HCV, including genotypes 1a, 1b, 2a, 3a and
4a. Side effects are similar to those reported for grazoprevir. High
SVR rates were achieved with combinations of these drugs in
patients with HCV infection, GrazoprevirþelbasvirþRBV resulted
in a SVR12 rate of, 93% in patients with HCV monoinfection and,
98% in patients who were co-infected with HIV. In another study
grazoprevirþelbasvirþRBV resulted in an SVR12 rate of, 97%.
Without RBV grazoprevirþelbasvir resulted in a SVR12 rate of
87%. SVR12 rates were similar whether or not patients had HCV
genotype 1a (92%) or genotype 1b (95%).4.3. Viekirax (ombitasvirþparitaprevirþritonavir)
In the Viekirax tablet25, the dosages of ombitasvir, paritaprevir,
ritonavir are increased from 12.5 to 25 mg, 75 to 150 mg and 50 to
100 mg, respectively. On January 16, 2015, the European Medi-
cines Agency has approved Viekirax and Exviera (Asunaprevir,
250 mg, twice daily) with or without RBV for patients with
chronic HCV genotype 1 infections, including those with com-
pensated liver cirrhosis, HIV-1 co-infection, patients on opioid
substitution therapy and liver transplant recipients. Additionally,
Viekirax has been approved for use with RBV in genotype
4 chronic hepatitis C patients. Despite cure rates of 97%, FDA
has not yet approved Viekirax for clinical use. AbbVie has
presented late-breaking, preliminary phase IIIb data with Viekir-
axþExviera in chronic hepatitis C patients with renal impairment, (B) daclatasvir and (C) beclabuvir.
azoprevir and (B) elbasvir.
Anti-HCV agents 31at the International Liver Congress 2015 on April 25, 2015, and
hopes to get approval from FDA soon25.5. Conclusions
DAA's have changed the landscape of HCV therapy. The ﬁrst
generation HCV PIs began the new era of anti-HCV therapeutics,
but within two years, they were replaced by new and better DAAs.
With the second generation of DAAs “HCV cure” can be promised
to 95%–100% of patients. This generation of drugs is expensive
but new pricing strategies for resource limited countries are
expected to make these drugs available globally over the next
several years. Even better DAAs under investigation will go to
market soon. It is the dawn of a new era of therapy for HCV
infected persons around the world.
Acknowledgment
The editorial assistance of Dr. Robert Schooley is gratefully
acknowledged.
References
1. Ashfaq UA, Javed T, Rehman S, Nawaz Z, Riazuddin S. An overview
of HCV molecular biology, replication and immune responses. Virol J
2011;8:161–70.
2. Siliva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, Mcmonagle
P, et al. Antiviral activity of boceprevir monotherapy in treatment-
naïve subjects with chronic hepatitis C genotype 2/3. J Hepatol
2013;59:31–7.
3. Kwo PY. Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor
for the treatment of chronic hepatitis C infection. Ther Adv Gastro-
enterol 2012;5:179–88.
4. Lin T-I, Lenz O, Fanning G, Verbinnen T, Delouvroy F, Scholliers A,
et al. In vitro activity and preclinical proﬁle of TMC435350, a potent
hepatitis C virus protease inhibitor. Antimicrob Agents Chemother
2009;53:1377–85.
5. Cunningham M, Foster GR. Efﬁcacy and safety of telaprevir in
patients with genotype 1 hepatitis C infection. Ther Adv Gastroenterol
2012;5:139–51.
6. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, DeJesus E,
McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/
ribavirin in treatment-naïve patients with HCV genotype 1: a rando-
mized, 28-day, dose-ranging trial. J Hepatol 2013;58:663–8.
7. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C,
Zennou V, et al. Genotype and subtype proﬁling of PSI-7977 as a
nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother
2012;56:3359–68.
8. Lenz O, Verbinnen T, Lin TI, Vijgen L, Cummings MD, Lindberg J,
et al. In vitro resistance proﬁle of the hepatitis C virus NS3/4A
protease inhibitor TMC435. Antimicrob Agents Chemother
2010;54:1878–87.
9. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV,
et al. Simeprevir with pegylated interferon α 2a plus ribavirin in
treatment-naïve patients with chronic hepatitis C virus genotype
1 infection (QUEST-1): a phase 3, randomised, double-blind, pla-
cebo-controlled trial. Lancet 2014;384:403–13.
10. Link JO, Taylor JG, Xu L, Michell M, Guo H, Liu H, et al. Discovery
of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for
the treatment of hepatitis C virus infection. J Med Chem
2014;57:2033–46.11. Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG,
et al. Virologic response following combined ledipasvir and sofosbuvir
administration in patients with HCV genotype 1 and HIV co-infection.
JAMA 2015;313:1232–9.
12. Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, et al.
In vitro and in vivo antiviral activity and resistance proﬁle of
ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents
Chemother 2015;59:979–87.
13. Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu LJ,
et al. In vitro and in vivo antiviral activity and resistance proﬁle of the
hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob
Agents Chemother 2015;59:988–97.
14. Kati W, Koey G, Irvin M, Beyer J, Liu Y, Krishnan P, et al. In vitro
activity and resistance proﬁle of dasabuvir, a nonnucleoside hepatitis C
virus polymerase inhibitor. Antimicrob Agents Chemother
2015;59:1505–11.
15. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al.
Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and
ribavirin for hepatitis C in patients co-infected with HIV-1: a
randomized trial. JAMA 2015;313:1223–31.
16. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron
A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97%
and 100% sustained virologic response with or without ribavirin in
treatment-experienced patients with HCV genotype 1b infection.
Gastroenterology 2014;147:359–65.
17. Scola PM, Sun LQ, Wang AX, Chen J, Sin N, Venables BL, et al. The
discovery of asunaprevir (BMS-650032), an orally efﬁcacious NS3
protease inhibitor for the treatment of hepatitis C virus infection. J Med
Chem 2014;57:1730–52.
18. Wang CF, Jia LL, Qiu DK, Valero L, Huang X, Sun JH, et al. In vitro
activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.
Antimicrob Agents Chemother 2012;56:1588–90.
19. Lemm JA, Liu M, Gentles RG, Ding M, Voss S, Pelosi LA, et al.
Preclinical characterization of BMS-791325, an allosteric inhibitor of
hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother
2014;58:3485–95.
20. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, Herring R, et al.
Daclatasvir in combination with asunaprevir and beclabuvir for
hepatitis C virus genotype 1 infection with compensated cirrhosis.
JAMA 2015;313:1736–44.
21. Summa V, Ludmerer SW, McCauley JA, Fandozzi C, Burlein C,
Claudio G, et al. MK-5172, a selective inhibitor of hepatitis C virus
NS3/4a protease with broad activity across genotypes and resistant
variants. Antimicrob Agents Chemother 2012;56:4161–7.
22. Coburn CA, Meinke PT, Chang W, Fandozzi CM, Graham DJ, Hu B,
et al. Discovery of MK-8742: an HCV NS5A inhibitor with broad
genotype activity. ChemMedChem 2013;8:1930–40.
23. Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyarder D,
et al. Efﬁcacy and safety of 12 weeks versus 18 weeks of treatment
with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without
ribavirin for hepatitis C virus genotype 1 infection in previously
untreated patients with cirrhosis and patients with previous null
response with or without cirrhosis (C-WORTHY): a randomised,
open-label phase 2 trial. Lancet 2015;385:1075–86.
24. Sulkowski MS, Hezode C, Gerstoft J, Vierling JM, Mallolas J, Pol S,
et al. Efﬁcacy and safety of MK-5172þMK-87427ribavirin in HCV
mono-infected and HIV/HCV co-infected treatment-naïve, non-cirrho-
tic patients with hepatitis C virus genotype 1 infection: the
C-WORTHY study (ﬁnal results, parts A and B). In: Proceedings of
the 65th Annual Meeting of the American Association for the Study of
Liver Diseases (AASLD). 7–11 Nov. Boston, US: AASLD; 2014.
25. Abb Vie presents late-breaking, preliminary phase 3b data with
VIEKIRAXs þ EXVIERAs in chronic hepatitis C patients with
renal impairment at the International Liver Congress TM 2015. Vienna,
Austria; 25 April 2015.
